
This study highlights the potential value of innovative ways of collecting information about adverse drug events directly from patients.
This study highlights the potential value of innovative ways of collecting information about adverse drug events directly from patients.
Despite almost universal testing for human-epidermal-growth-factor-receptor-2 (HER2), many women with a HER2-positive cancer may not receive trastuzumab. Fewer women received the newer gene-expression-profile (GEP) test.
Published: May 15th 2011 | Updated:
Published: June 1st 2004 | Updated:
Published: February 1st 2004 | Updated:
Published: November 16th 2012 | Updated:
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.